A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.
about
Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilitiesCurrent status and prospects for development of an HSV vaccineProspects and perspectives for development of a vaccine against herpes simplex virus infections.Development and utilization of a custom PCR array workflow: analysis of gene expression in mycoplasma genitalium and guinea pig (Cavia porcellus).Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challengeA novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in miceA Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell ImmunogensProtection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases.A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.Nucleic acid vaccination strategies against infectious diseases.Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents.Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.Clinical management of herpes simplex virus infections: past, present, and future
P2860
Q31152863-96322F16-2994-4315-B5CA-6B923F9BE1CCQ33931016-75225213-BC21-4C3E-BAE6-1670A5E3537EQ34431547-4111F842-6207-4286-9AE8-78D0AB5D6030Q34983643-C5DA8E06-2251-4060-8EA6-B808BD1CDDAAQ34992660-0B15FE16-BA17-4C82-852F-A4FE5609E48AQ35009410-B9D9FCF8-F9E9-4DD8-8E13-1824B2EDD87AQ35914367-A3B9A2FF-2746-4C21-9C73-0FEC4858922DQ36553837-0033B515-037C-4239-8389-523BDB0C4E39Q37530461-F15519F7-AF80-490C-A4E1-49D61D9F53EBQ37561211-E72323E1-3E12-40B7-B892-7DB805B81343Q37611796-34704C6E-E9FF-4268-A706-183C30E5C2A0Q38212516-17E3D40D-A2E2-48A2-8EF9-A1DAEC88FDBFQ38342834-98B06634-E948-486C-9767-54F40121B455Q38353693-772BE8B0-B34D-462B-ACEF-F8B55715667BQ38586079-1301D5A2-D18C-4F30-A583-7550B3374BADQ40121437-90F54CFD-FE35-4B1C-9E71-DB4EF5534437Q40530389-6FEB9D7D-E7FD-48C5-9071-801CCCDCDCF6Q41928445-E0C43911-0350-4427-9D95-B6916B0EA85DQ42079721-05705AB6-A4A3-4DDE-9668-CF8BD62D6E44Q59133817-2206FE17-9DD8-450A-BDE6-4ADE88895911
P2860
A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Vaxfectin
@nl
A Vaxfectin(®)-adjuvanted HSV- ...... a pig model of genital herpes.
@en
type
label
A Vaxfectin
@nl
A Vaxfectin(®)-adjuvanted HSV- ...... a pig model of genital herpes.
@en
prefLabel
A Vaxfectin
@nl
A Vaxfectin(®)-adjuvanted HSV- ...... a pig model of genital herpes.
@en
P2093
P2860
P1433
P1476
A Vaxfectin(®)-adjuvanted HSV- ...... a pig model of genital herpes.
@en
P2093
Mark Shlapobersky
Nigel Bourne
Richard B Pyles
Ronald L Veselenak
Sean M Sullivan
P2860
P304
P356
10.1016/J.VACCINE.2012.09.057
P407
P577
2012-10-04T00:00:00Z